Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade plus fludarabine versus rituximab plus fludarabine in previously rituximab-treated recurrent advanced follicular lymphoma
2007-004151-11Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL) comparing Velcade + Fludara with MabThera + Fludara (2 arms). Primary endpoint: Complete response rate. Started Mar 2009; status: completed.
02
Drugs
bortezomibrituximabfludarabine
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2007-004151-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004151-11.